BG Medicine Fails to Regain Nasdaq Listing Compliance | GenomeWeb

NEW YORK (GenomeWeb News) – Nasdaq has notified BG Medicine that the company has not regained compliance with a listing requirement calling for at least $50 million in market value of its listed securities for continued listing on the exchange, BG Medicine said in a regulatory document.

In the document filed with the US Securities and Exchange Commission on Friday, the company said that it received written notice from Nasdaq's staff of the listing qualifications department on Nov. 14. As a result of the finding, BG Medicine may be delisted from Nasdaq.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: CRISPR-based approach to identify gene variants, and more.

Stat News profiles the Wellcome Trust's Jeremy Farrar.

France's research minister tells Nature News that he hopes to simplify the research bureaucracy and improve funding.

A recent study examines how a paper, despite being retracted, can influence its field, Retraction Watch reports.